Open Label Study of OTO-104 in Subjects With Meniere's Disease
Launched by OTONOMY, INC. · Apr 11, 2016
Trial Information
Current as of July 21, 2025
Terminated
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria includes, but is not limited to:
- • Subject has a diagnosis of definite unilateral Meniere's disease.
- • Subject agrees to maintain their current standard of care treatments for Meniere's disease while on-study.
- Exclusion Criteria includes, but is not limited to:
- • Subject has an infection in the ear, sinuses, or upper respiratory system.
- • Subject is pregnant or lactating.
- • Subject has a history of immunodeficiency disease.
- • Subject has active or recent (\<1 month prior to screening) middle ear disease, including but not limited to: chronic otitis media, acute otitis media, middle ear effusions, middle ear atelectasis, or cholesteatoma.
- • Subject has experienced an adverse reaction to intratympanic injection of steroids.
About Otonomy, Inc.
Otonomy, Inc. is a biopharmaceutical company focused on developing innovative therapeutics for the treatment of ear disorders. With a commitment to advancing patient care, Otonomy leverages its proprietary drug delivery technologies to address unmet medical needs in conditions such as hearing loss and chronic ear diseases. The company's robust pipeline includes both clinical and preclinical programs aimed at providing effective and long-lasting treatment options. Otonomy is dedicated to improving the lives of patients through scientific excellence and a patient-centered approach to drug development.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
London, Ontario, Canada
Patients applied
Trial Officials
Kathie Bishop, PhD
Study Chair
Otonomy, Inc.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials